Literature DB >> 22290956

Dynamic interaction between fluconazole and amphotericin B against Cryptococcus gattii.

Julliana Ribeiro Alves Santos1, Ludmila Ferreira Gouveia, Erika Linzi Silva Taylor, Maria Aparecida Resende-Stoianoff, Gerson Antônio Pianetti, Isabela Costa César, Daniel Assis Santos.   

Abstract

Cryptococcus gattii is the main pathogen of cryptococcosis in healthy patients and is treated mainly with fluconazole and amphotericin B. The combination of these drugs has been questioned because the mechanisms of action could lead to a theoretical antagonistic interaction. We evaluated distinct parameters involved in the in vitro combination of fluconazole and amphotericin B against Cryptococcus gattii. Fourteen strains of C. gattii were used for the determination of MIC, fractional inhibitory concentration, time-kill curve, and postantifungal effect (PAFE). Ergosterol quantification was performed to evaluate the influence of ergosterol content on the interaction between these antifungals. Interaction between the drugs varied from synergistic to antagonistic depending on the strain and concentration tested. Increasing fluconazole levels were correlated with an antagonistic interaction. A total of 48 h was necessary for reducing the fungal viability in the presence of fluconazole, while 12 h were required for amphotericin B. When these antifungals were tested in combination, fluconazole impaired the amphotericin B activity. The ergosterol content decreased with the increase of fluconazole levels and it was correlated with the lower activity of amphotericin B. The PAFE found varied from 1 to 4 h for fluconazole and from 1 to 3 h for amphotericin B. The interaction of fluconazole and amphotericin B was concentration-dependent and special attention should be directed when these drugs are used in combination against C. gattii.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22290956      PMCID: PMC3346628          DOI: 10.1128/AAC.06098-11

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  25 in total

Review 1.  Combination chemotherapy for invasive fungal infections: what laboratory and clinical studies tell us so far.

Authors:  Dimitrios P Kontoyiannis; Russell E Lewis
Journal:  Drug Resist Updat       Date:  2003-10       Impact factor: 18.500

2.  Synergy, antagonism, and what the chequerboard puts between them.

Authors:  F C Odds
Journal:  J Antimicrob Chemother       Date:  2003-06-12       Impact factor: 5.790

Review 3.  Combination antifungal therapy.

Authors:  Melissa D Johnson; Conan MacDougall; Luis Ostrosky-Zeichner; John R Perfect; John H Rex
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

4.  Itraconazole-amphotericin B antagonism in Aspergillus fumigatus: an E-test-based strategy.

Authors:  D P Kontoyiannis; R E Lewis; N Sagar; G May; R A Prince; K V Rolston
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

Review 5.  Cryptococcus gattii: an emerging fungal pathogen infecting humans and animals.

Authors:  Edmond J Byrnes; Karen H Bartlett; John R Perfect; Joseph Heitman
Journal:  Microbes Infect       Date:  2011-06-01       Impact factor: 2.700

6.  Interactions between triazoles and amphotericin B against Cryptococcus neoformans.

Authors:  F Barchiesi; A M Schimizzi; F Caselli; A Novelli; S Fallani; D Giannini; D Arzeni; S Di Cesare; L F Di Francesco; M Fortuna; A Giacometti; F Carle; T Mazzei; G Scalise
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

7.  Postantifungal effect and effects of sub-MIC concentrations on previously treated Candida sp. influence of growth phase.

Authors:  M T García; M T Llorente; F Mínguez; J Prieto
Journal:  J Infect       Date:  2002-11       Impact factor: 6.072

8.  In vitro evaluation of combination of terbinafine with itraconazole or amphotericin B against Zygomycota.

Authors:  Alicia Gómez-López; Manuel Cuenca-Estrella; Emilia Mellado; Juan L Rodríguez-Tudela
Journal:  Diagn Microbiol Infect Dis       Date:  2003-03       Impact factor: 2.803

9.  Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans.

Authors:  E J Ernst; M E Klepser; M A Pfaller
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

Review 10.  Fluconazole resistance in Candida albicans: a review of mechanisms.

Authors:  I A Casalinuovo; P Di Francesco; E Garaci
Journal:  Eur Rev Med Pharmacol Sci       Date:  2004 Mar-Apr       Impact factor: 3.507

View more
  19 in total

Review 1.  Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients.

Authors:  Romuald Bellmann; Piotr Smuszkiewicz
Journal:  Infection       Date:  2017-07-12       Impact factor: 3.553

2.  2-(benzylideneamino)phenol: a promising hydroxyaldimine with potent activity against dermatophytoses.

Authors:  Alan Kiill Gasparto; Ludmila Matos Baltazar; Ludmila Ferreira Gouveia; Cleiton Moreira da Silva; Ricardo Martins Duarte Byrro; Milene Alvarenga Rachid; Armando da Silva Cunha Júnior; Maria Aparecida de Resende-Stoianoff; Angelo de Fátima; Daniel Assis Santos
Journal:  Mycopathologia       Date:  2014-12-17       Impact factor: 2.574

3.  Heteroresistance to Itraconazole Alters the Morphology and Increases the Virulence of Cryptococcus gattii.

Authors:  Gabriella Freitas Ferreira; Julliana Ribeiro Alves Santos; Marliete Carvalho da Costa; Rodrigo Assunção de Holanda; Ângelo Márcio Leite Denadai; Gustavo José Cota de Freitas; Áquila Rodrigues Costa Santos; Priscila Batista Tavares; Tatiane Alves Paixão; Daniel Assis Santos
Journal:  Antimicrob Agents Chemother       Date:  2015-05-26       Impact factor: 5.191

4.  Environmental Triazole Induces Cross-Resistance to Clinical Drugs and Affects Morphophysiology and Virulence of Cryptococcus gattii and C. neoformans.

Authors:  Rafael Wesley Bastos; Hellem Cristina Silva Carneiro; Lorena Vívien Neves Oliveira; Karen Maia Rocha; Gustavo José Cota Freitas; Marliete Carvalho Costa; Thaís Furtado Ferreira Magalhães; Vanessa Silva Dutra Carvalho; Cláudia Emanuela Rocha; Gabriella Freitas Ferreira; Tatiane Alves Paixão; Frédérique Moyrand; Guilhem Janbon; Daniel Assis Santos
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

5.  Fluconazole alters the polysaccharide capsule of Cryptococcus gattii and leads to distinct behaviors in murine Cryptococcosis.

Authors:  Julliana Ribeiro Alves Santos; Rodrigo Assunção Holanda; Susana Frases; Mayara Bravim; Glauber de S Araujo; Patrícia Campi Santos; Marliete Carvalho Costa; Maira Juliana Andrade Ribeiro; Gabriella Freitas Ferreira; Ludmila Matos Baltazar; Aline Silva Miranda; Danilo Bretas Oliveira; Carolina Maria Araújo Santos; Alide Caroline Lima Fontes; Ludmila Ferreira Gouveia; Maria Aparecida Resende-Stoianoff; Jonatas Santos Abrahão; Antônio Lúcio Teixeira; Tatiane Alves Paixão; Danielle G Souza; Daniel Assis Santos
Journal:  PLoS One       Date:  2014-11-13       Impact factor: 3.240

6.  Quantitation of ergosterol content and gene expression profile of ERG11 gene in fluconazole-resistant Candida albicans.

Authors:  F Alizadeh; A Khodavandi; S Zalakian
Journal:  Curr Med Mycol       Date:  2017-03

7.  Eugenol Induces Phenotypic Alterations and Increases the Oxidative Burst in Cryptococcus.

Authors:  Júnia C O Alves; Gabriella F Ferreira; Julliana R Santos; Luís C N Silva; João F S Rodrigues; Wallace R N Neto; Emmanueli I Farah; Áquila R C Santos; Brenda S Mendes; Lourimar V N F Sousa; Andrea S Monteiro; Vera L Dos Santos; Daniel A Santos; Andrea C Perez; Thiago R L Romero; Ângelo M L Denadai; Luciana S Guzzo
Journal:  Front Microbiol       Date:  2017-12-07       Impact factor: 5.640

8.  Treatment with pCramoll Alone and in Combination with Fluconazole Provides Therapeutic Benefits in C. gattii Infected Mice.

Authors:  Jannyson J Jandú; Marliete C Costa; Julliana R A Santos; Fernanda M Andrade; Thais F Magalhães; Márcia V Silva; Maria C A B Castro; Luanna C B B Coelho; Aline G Gomes; Tatiane A Paixão; Daniel A Santos; Maria T S Correia
Journal:  Front Cell Infect Microbiol       Date:  2017-05-24       Impact factor: 5.293

9.  Inhibitory effect of magnetic iron-oxide nanoparticles on the pattern of expression of lanosterol 14α-demethylase (ERG11) in fluconazole-resistant colonising isolate of Candida albicans.

Authors:  Mohammad Zare-Khafri; Fahimeh Alizadeh; Sadegh Nouripour-Sisakht; Alireza Khodavandi; Majid Gerami
Journal:  IET Nanobiotechnol       Date:  2020-07       Impact factor: 1.847

Review 10.  Activity and Mechanism of Action of Antifungal Peptides from Microorganisms: A Review.

Authors:  Tianxi Li; Lulu Li; Fangyuan Du; Lei Sun; Jichao Shi; Miao Long; Zeliang Chen
Journal:  Molecules       Date:  2021-06-05       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.